Trial review
Tirzepatide and Type 2 Diabetes Prevention
Progression to type 2 diabetes
SURMOUNT-1, three-year prediabetes analysis was a prespecified analysis of a phase 3 randomised double-blind placebo-controlled trial funded by Eli Lilly and Company. Three years of tirzepatide produced substantial sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than placebo.
| Design | Prespecified analysis of a phase 3 randomised double-blind placebo-controlled trial |
|---|---|
| Population | The 1,032 SURMOUNT-1 participants who had both obesity and prediabetes |
| Sample size | 1,032 of 2,539 |
| Intervention | Tirzepatide once weekly |
| Comparator | Placebo |
| Duration | 176 weeks of treatment followed by a 17-week off-treatment period |
| Primary endpoint | Progression to type 2 diabetes, plus three-year weight change and safety |
| Main result | Three years of tirzepatide produced substantial sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than placebo |
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | Who was eligible | The 1,032 SURMOUNT-1 participants who had both obesity and prediabetes |
| 2 | What they received | Tirzepatide once weekly |
| 3 | What it was compared against | Placebo |
| 4 | For how long | 176 weeks of treatment followed by a 17-week off-treatment period |
| 5 | What was measured first | Progression to type 2 diabetes, plus three-year weight change and safety |
| 6 | What the group average was | Three years of tirzepatide produced substantial sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than placebo |
| 7 | What it does not tell you | A group average is not a prediction for any individual reader. |
Show this figure as a table
| Item | Weight change | Evidence |
|---|---|---|
| Intervention group | not captured | — |
| Comparator group | not captured | — |
| Question | Position |
|---|---|
| Average effect in the studied population | Reported once captured |
| Your individual outcome | Not predicted by any trial |
| Effect of a compounded preparation | Not studied here |
| Effect at doses outside the protocol | Not studied here |
| Effect after stopping | Only if the trial included a withdrawal phase |
| Long-term safety beyond the trial | Outside the observation window |
Who was studied?
The 1,032 SURMOUNT-1 participants who had both obesity and prediabetes
Registry and publication identifiers: NCT04184622 · DOI 10.1056/NEJMoa2410819. Sponsor: Eli Lilly and Company. Checked against the source on 2026-08-03.
What was given, and what was it compared against?
| Field | What the record states |
|---|---|
| Design | Prespecified analysis of a phase 3 randomised double-blind placebo-controlled trial |
| Intervention | Tirzepatide once weekly |
| Dose | 5 mg, 10 mg or 15 mg |
| Comparator | Placebo |
| Duration | 176 weeks of treatment followed by a 17-week off-treatment period |
| Primary endpoint | Progression to type 2 diabetes, plus three-year weight change and safety |
A placebo comparator is what allows a trial to claim the drug caused the difference. An active comparator answers a weaker question — whether the drug is at least as good as one already shown to work — and the two are routinely reported in the same words.
What did it find?
Three years of tirzepatide produced substantial sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than placebo
A trial result is a mean across a population, not a prediction for an individual. The same trial that produces an average contains people who did far better and people who did not respond, and a page quoting only the average is quoting the part that flatters it.
What were the adverse events and discontinuations?
Adverse events are reported in the primary publication.
What are the limitations?
Industry-funded. Applies to people with both obesity and prediabetes, not to the general population. The 17-week off-treatment period is short relative to a chronic condition, and delaying progression is not the same as preventing it permanently.
How should this be read, and how should it not?
- It describes the product that was studied. Every figure here was collected on the FDA-approved product. No compounded preparation has a trial of its own, and no figure on this page transfers to one.
- It describes the dose that was studied. A microdose sits below the range trialled here, so no result on this page applies to one at any price.
- It describes the population that was studied. A result in people with established cardiovascular disease does not transfer to primary prevention, and a result in diabetes does not transfer to weight management.
- It is not a dosing instruction. Your prescriber sets your regimen.
How does it compare with the other trials on this site?
| Trial | Intervention | Reported result | Duration |
|---|---|---|---|
| SURMOUNT-1, three-year prediabetes analysis | Tirzepatide once weekly | Three years of tirzepatide produced substantial sustained weight reduction and a markedly | 176 weeks of treatment |
| ATTAIN-1 | Orforglipron, once-daily oral non- | Approximately 11% to 12.4% mean weight reduction at the highest dose over 72 weeks. Lilly | 72 weeks |
| OASIS 4 | Oral semaglutide 25 mg once daily, | 13.6% mean weight reduction on the treatment-policy estimand versus 2.2% placebo; 16.6% ve | 64 weeks of treatment |
| SELECT | Semaglutide | Approximately a 20% relative reduction in the primary composite; event rate fell from roug | Mean follow-up approxi |
| STEP-1 | Semaglutide | Mean weight change of −14.9% against −2.4% on placebo; about 86% reached 5% or more, about | 68 weeks |
| STEP-8 | Semaglutide 2.4 mg weekly | Mean weight change approximately −15.8% on semaglutide against approximately −6.4% on lira | 68 weeks |
| SUMMIT | Tirzepatide once weekly at maximum | A 38% reduction in the combined endpoint of cardiovascular death and worsening heart-failu | 52 weeks to the sympto |
| SURMOUNT-1 | Tirzepatide once weekly | Treatment-regimen estimand: −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg) versus −3.1% pla | 72 weeks |
| SURMOUNT-3 | not stated | −18.4% additional reduction versus +2.5% with placebo, on top of lead-in weight loss | 72 weeks |
| SURMOUNT-4 | not stated | Participants who continued lost a further 5.5%. Participants withdrawn to placebo regained | 88 weeks total, 36-wee |
Separate trials with different populations, durations and endpoints. Only a head-to-head supports a direct comparison between two drugs; the rest sit side by side here for reference, not for subtraction.
Frequently asked questions
Does this mean I would lose that much weight?
No. Trials report group averages under controlled conditions with specific eligibility criteria. Individual results vary widely, and the trial population may not resemble you.
Do these results apply to compounded tirzepatide?
Not automatically. Trials studied the approved product at studied doses. A compounded preparation at a different concentration, formulation or route has not been through those trials.
Related on this site
- Research hubResearch
- SURMOUNT-1 Tirzepatide Trial ExplainedResearch
- SURMOUNT-3 Tirzepatide Trial ExplainedResearch
- SURMOUNT-4: Weight Maintenance and Tirzepatide WithdrawalResearch
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- SUMMIT Trial: Tirzepatide and HFpEFResearch
- Tirzepatide vs Semaglutide: What the Head-to-Head Trial ShowsJournal
- Tirzepatide for Type 2 DiabetesResearch
Related coverage
GLP-1 Semaglutide Rx. “Tirzepatide and Type 2 Diabetes Prevention.” S.J Partners LLC, 2026-08-03. https://glp1semaglutiderx.com/research/tirzepatide-diabetes-prevention/
Quote the capture date beside a figure, not the date you read this page. Why.